NCT03014830View on ClinicalTrials.gov

Alirocumab and Reverse Cholesterol Transport

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

June 4, 2018

Study Completion Date

July 30, 2018

Conditions
AtherosclerosisCoronary Heart Disease
Interventions
DRUG

Alirocumab

150 mg SQ every 2 weeks

DRUG

Placebos

Placebo injections SQ every 2 weeks

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT03014830 - Alirocumab and Reverse Cholesterol Transport | Biotech Hunter | Biotech Hunter